Consider the Following Clinical Guidelines
When Initiating Iron Therapy in Adult CRI
Patients With IDA

Key guidelines recommend monitoring iron levels and intervening when iron deficiency anemia (IDA) is present^7,16:

• The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI™)
  in non-dialysis patients⁷


• The National Comprehensive Cancer Network (NCCN) in patients with cancer- or
  chemotherapy-induced anemia¹⁶
  
  
  • While the NCCN guidelines below apply to cancer patients who are receiving myelosuppressive chemotherapy without curative intent, these guidelines may also be useful for your
    adult CRI patients with IDA
• CRI is prevalent in cancer patients with IDA
  

KDOQI™ Guidelines refer to patients with chronic renal insufficiency (CRI) as having chronic kidney disease (CKD), while others refer to them as having end-stage renal disease (ESRD) in more severe cases. CKD, CRI, and ESRD all refer to kidney disease.

• Initial treatment considerations for adult CRI patients with IDA may include oral iron, IV iron, or erythropoiesis stimulating agent (ESA)⁷


• Iron agents may serve as primary therapy or adjuvant therapy in patients receiving ESAs


• As adjuvant therapy to ESAs, iron agents can help:


• Prevent iron deficiency


• Maximize the efficiency of ESA therapy and potentially minimize the dose needed to reach target Hgb levels

• Iron status tests should be performed every month during initial ESA treatment and at least every 3 months during stable ESA treatment⁷


• Adult CRI patients receiving oral iron should be evaluated frequently to check for treatment failure


• Failure may be due to a diminished ability to absorb iron or to poor patient compliance⁷

Hgb=hemoglobin; IV=intravenous; TSAT=transferrin saturation.
KDOQI is a trademark of the National Kidney Foundation, Inc.

Now that you know about Clinical Practice Guidelines, learn more about Patient Identification.